文献速递小儿耳鼻咽喉咽喉与嗓音

术后口服地塞米松对儿童扁桃体切除术后疼痛的影响:随机临床试验

Postoperative Oral Dexamethasone and Pediatric Tonsillectomy Morbidity: A Randomized Clinical Trial.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2026-01-01

该四盲随机临床试验纳入209例3-17岁腺扁桃体切除术患儿,比较术后第2、4、6天口服地塞米松(0.5 mg/kg,最大20 mg)与安慰剂的镇痛效果。结果显示地塞米松组术后第2-8天用药前疼痛评分平均降低0.72分(95%CI 0-1.44),但置信区间宽且基线疼痛存在差异,无法得出肯定结论;地塞米松组阿片类药物处方(OR 0.23,95%CI 0.06-0.84)和因疼痛急诊就诊(OR 0.12,95%CI 0.003-0.91)的 odds 显著降低,但精确性有限,且未增加并发症。

要点

  • 术后口服地塞米松可能适度减轻儿童腺扁桃体切除术后疼痛。
  • 地塞米松显著降低阿片类药物处方和疼痛相关急诊就诊的 odds。
  • 未观察到地塞米松增加再入院、出血等并发症。

核心结论

  • 术后口服地塞米松与儿童腺扁桃体切除术后疼痛适度减轻相关,并大幅减少阿片类药物处方,且不增加并发症,支持其作为镇痛辅助用药。

研究设计与样本

  • 平行设计四盲随机临床试验,单中心三级学术中心,纳入3-17岁腺扁桃体切除术患儿,2021年8月至2023年5月入组,疼痛随访14天,不良事件随访5-9周。
  • 共筛查763名儿童,209例纳入不良事件和医疗利用分析(地塞米松组104例,安慰剂组105例),其中131例(地塞米松组61例,安慰剂组70例)完成疼痛日记并纳入主要疼痛结局分析。

主要发现

  • 术后第2-8天用药前疼痛评分地塞米松组平均4.12(SD 2.00),安慰剂组平均4.84(SD 2.15),平均差0.72分(95%CI 0-1.44) favoring 地塞米松,但置信区间宽且用药前疼痛存在差异,无法得出肯定结论。
  • 术后第12和13天,地塞米松组用药前后疼痛均较低(平均差0.96-2.37分)。
  • 地塞米松组接受阿片类药物处方的 odds 显著降低(OR 0.23,95%CI 0.06-0.84),因疼痛急诊就诊的 odds 显著降低(OR 0.12,95%CI 0.003-0.91),但估计精确性有限。
  • 再入院、护理电话、扁桃体切除术后出血和恢复正常饮食的组间差异小且无临床意义。

关键数值与推荐

  • 干预方案:术后第2、4、6天口服地塞米松0.5 mg/kg(最大剂量20 mg)或安慰剂。
  • 主要结局:术后第2-8天给药前平均疼痛评分。

临床怎么用

  • 可考虑将术后短期口服地塞米松作为儿童腺扁桃体切除术的镇痛辅助用药,以减少阿片类药物使用和疼痛相关急诊就诊。
  • 需注意主要疼痛结局的置信区间宽且基线疼痛存在差异,疗效证据尚不确切,临床决策应个体化。

局限性

  • 主要疼痛分析仅纳入131/209例完成疼痛日记的患儿,可能存在选择偏倚。
  • 疼痛评分的95%置信区间宽且组间用药前疼痛存在差异,限制了疗效结论的确定性。
  • 不良事件和医疗利用结局的估计精确性有限,影响可解释性。
  • 单中心研究,外推性需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Tonsillectomy is among the most painful otolaryngologic procedures. It is unclear whether a postoperative course of oral steroids reduces pediatric tonsillectomy pain and morbidity. OBJECTIVE: To determine whether a postoperative course of oral dexamethasone reduces postadenotonsillectomy pain in children. DESIGN, SETTING, AND PARTICIPANTS: This was a parallel-design quadruple-blinded randomized clinical trial conducted at a single tertiary academic center that enrolled pediatric patients (3-17 years of age) undergoing adenotonsillectomy from August 2021 to May 2023, with 14 days of follow-up for pain and 5 to 9 weeks for adverse events. Data were analyzed from October 2023 to May 2026. INTERVENTION: Oral dexamethasone (0.5 mg/kg; maximum dose, 20 mg) or placebo on postoperative days 2, 4, and 6. MAIN OUTCOME AND MEASURE: Mean (SD) pain score before medication administered during days 2 to 8 postoperatively. RESULTS: Of 763 children screened, 209 participants (median [IQR] age, 7.1 [5.8] years; 99 females [47.4%] and 110 males [52.6%]) were included (104 to the steroid arm and 105 to placebo) in analyses of adverse events and health care utilization. Of these, 131 (61 steroid arm and 70 placebo) completed pain diaries and were included in primary outcome (pain) analysis. Mean (SD) pain before acetaminophen or ibuprofen on days 2 to 8 was 0.72 (95% CI, 0-1.44) points lower in the dexamethasone group (4.12 [2.00]) than placebo (4.84 [2.15]), but wide 95% CIs and differences in pain prior to taking the study medication prevented making definitive conclusions. The dexamethasone group had less pre- and postanalgesic pain on postoperative days 12 and 13 (mean difference, 0.96-2.37 points) and a considerable decrease in odds of receiving an opioid prescription (odds ratio [OR], 0.23; 95% CI, 0.06-0.84) or having an emergency department visit for pain (OR, 0.12; 95% CI, 0.003-0.91). However, the precision of these estimates limits interpretability. Differences in readmissions, nursing telephone calls, posttonsillectomy hemorrhage, and return to normal diet between groups were small and clinically meaningless. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, postoperative oral dexamethasone was associated with a modest reduction in pain after pediatric adenotonsillectomy, a considerable reduction in opioid prescriptions, and no increase in complications, supporting its use as an analgesic adjunct. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04879823.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Shaffer AD, Omar M, Maguire RC, et al. Postoperative Oral Dexamethasone and Pediatric Tonsillectomy Morbidity: A Randomized Clinical Trial. JAMA Otolaryngol Head Neck Surg. 2026. PMID: 42490074. doi:10.1001/jamaoto.2026.1910

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。